Question

I am a breastfeeding mother and i want to know if it is safe to use Eprosartan Mesilate? Is Eprosartan Mesilate safe for nursing mother and child? Does Eprosartan Mesilate extracts into breast milk? Does Eprosartan Mesilate has any long term or short term side effects on infants? Can Eprosartan Mesilate influence milk supply or can Eprosartan Mesilate decrease milk supply in lactating mothers?

Eprosartan Mesilate lactation summary

Eprosartan Mesilate usage has low risk in breastfeeding
  • DrLact safety Score for Eprosartan Mesilate is 3 out of 8 which is considered Low Risk as per our analyses.
  • A safety Score of 3 indicates that usage of Eprosartan Mesilate may cause some minor side effects in breastfed baby.
  • Our study of different scientific research indicates that Eprosartan Mesilate may cause moderate to no side effects in lactating mother.
  • Most of scientific studies and research papers declaring usage of Eprosartan Mesilate low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • While using Eprosartan Mesilate We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About Eprosartan Mesilate usage in lactation

At latest update, relevant published data on excretion into breast milk were not found. A high protein-binding capacity makes excretion into breast milk unlikely. In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption. Case report of kidney function impairment of a baby whose mother had taken Telmisartan in pregnancy. Until more data on this medication is available, safer alternative drugs are preferred, especially in premature babies or during the neonatal period. Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.